Citizens Financial price target raised to $52 from $44 at BofA
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Arista May Outpace Peers With 25% Growth
Arista Networks (NYSE:ANET) opened up 14% Wednesday after smashing Q2 expectations on booming cloud and data center spending. They delivered a 65.6% gross margin, beating guidance of 63% and the Street's 62.9%, while operating margin hit 48.8% versus a 46% forecast. Free cash flow came in at $1.18 billion, well above the $852 million consensus and even BofA's $1.02 billion model. Management now sees 25% revenue growth in 2025, up from 17%, as hyperscalers pour capex into both back-end and front-end cloud networks. Warning! GuruFocus has detected 6 Warning Sign with ANET. Analysts couldn't wait to react: BofA bumped its price target to $155, KeyBanc raised theirs to $145, and J.P. Morgan lifted theirs to $150, all keeping bullish calls. J.P. Morgan's team says Arista could hit $10 billion in revenue by 2026two years ahead of planand that AI network rollouts will keep momentum going into 2027. If Arista can sustain these margins and ride the cloud capex wave, it may leave legacy peers in the will be tuning in to the next earnings report for proof that the cloud boom isn't over. This article first appeared on GuruFocus.
CNBC
a day ago
- CNBC
Bank of America CEO responds to Trump's claim he was rejected as a customer
CNBC's Andrew Ross Sorkin sits down with Brian Moynihan, Bank of America CEO, to discuss his reaction to President Trump's comments on 'Squawk Box' alleging that BofA rejected him as a customer, whether BofA is concerned about retribution, and much more.
Yahoo
a day ago
- Yahoo
Krystal Biotech price target lowered to $182 from $192 at BofA
BofA analyst Alec Stranahan lowered the firm's price target on Krystal Biotech (KRYS) to $182 from $192 and keeps a Buy rating on the shares. While there were some positives from the Q2 report, the firm expects investors will be concerned about the near-term growth trajectory given management expects Q3 revenue to be below Q2 based on patient pausing trends. Following the quarterly report, the firm updated its model to reflect decreased near-term Vyjuvek revenues and pushed back launches for KB407 and KB408. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on KRYS: Disclaimer & DisclosureReport an Issue Krystal Biotech: Strong Financial Performance and Strategic Global Expansion Justify Buy Rating Video: Why These Stocks Are Moving Today Krystal Biotech reports Q2 EPS $1.29, consensus $1.44 Is KRYS a Buy, Before Earnings? Positive Phase 1 Trial Results for KB304 Bolster Buy Rating for Krystal Biotech Amidst Promising Market Potential Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
